echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Bids will be opened this Friday! The latest meeting minutes flowed out of the second round of centralized procurement key points to see first

    Bids will be opened this Friday! The latest meeting minutes flowed out of the second round of centralized procurement key points to see first

    • Last Update: 2020-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The second round of centralized purchase is planned to be opened on Friday (January 17) In a few days before the opening, the latest minutes of the meeting are also circulated in the industry Near the bid opening, combined with the latest news, we have a brief review of 33 varieties of corresponding enterprises, over evaluation and some highlights Amoxicillin, glimepiride and other shortlisted enterprises can reach 5 on December 29, 2019 Shanghai Sunshine pharmaceutical purchasing network released the announcement of national drug centralized procurement document (gy-yd2019-2), which published the second round of centralized procurement catalog, 33 varieties were shortlisted Acarbose, amoxicillin, aniracetam tablets, glimepiride, etc are among the best Different from the first two rounds of belt quantity procurement, the maximum number of shortlisted enterprises can be up to 6 if the actual number of declared enterprises for new belt quantity procurement is ≥ 9; the maximum number of shortlisted enterprises can be up to 5 if the actual number of declared enterprises is 7-8; the maximum number of shortlisted enterprises can be up to 4 if the actual number of declared enterprises is 5-6, as shown in the following figure: the actual number of declared enterprises and the maximum number of shortlisted Enterprises According to the data in the above table, Sina Medicine found that amoxicillin met the largest number of applicant groups, up to 8, including UL, Sinopharm, Hunan Kelun, Jinhua Kangenbei, ankehengyi, Rukang medicine, Guilin south medicine, Hunan Xiansheng, followed by glimepiride, moxifloxacin, zuoxitirizin, up to 7, According to the rules, the maximum number of enterprises shortlisted for these varieties can reach 5 On the whole, the number of qualified enterprises is mostly about 3, and the competition is expected to remain fierce Qilu pharmaceutical, Yangzijiang and other related products are the most in this centralized procurement, and Qilu pharmaceutical, Yangzijiang and Shiyao group (including subsidiaries) are the most in domestic enterprises, reaching 7 Among them, Qilu pharmaceutical mainly includes adefovir dipivoxil tablets, trimetazidine hydrochloride sustained-release tablets, sulindanin Succinate Tablets, tegio capsules, levocetirizine hydrochloride tablets, tadalafil tablets, paclitaxel for injection (albumin binding type) It is worth mentioning that in the previous 4 + 7 expansion, Qilu pharmaceutical won the bid for 5 varieties, and in some varieties, Qilu pharmaceutical was the most competitive Atorvastatin of Qilu Pharmaceutical (Hainan) won the bid at 1.68 yuan / box, and its gefitinib was directly reduced to 257 yuan Therefore, the price of Qilu Pharmaceutical Co., Ltd is also attracting attention, or will continue to bring pressure to the same varieties In addition, Sichuan Kelun, Hengrui (including Chengdu Shengdi pharmaceutical) and other related varieties are closely followed, which is also a big point after the bid opening Bayer has the largest number of products in the original research enterprise, including three varieties and four specifications, mainly including acarbose, magnesium aluminate and moxifloxacin; GlaxoSmithKline, Pfizer and Servier have two varieties At present, a total of 26 foreign enterprises are likely to participate in this round of centralized procurement bidding The foreign enterprises winning the bid for 4 + 7 volume procurement are AstraZeneca and Shanghai Squibb pharmaceutical of China and the United States In addition, 5 foreign enterprises including Sanofi, Lilly, MSD, Sandoz and India redI were added when winning the bid for 4 + 7 expansion Now, the influence of 4 + 7 is obvious, and foreign enterprises have actively participated in the centralized procurement since the previous wait-and-see attitude For example, in the 4 + 7 expansion, Lilly is the same as domestic Huiyu pharmaceutical The varieties will be selected together with the price reduction, so it is expected that the participation of Chinese and foreign drugs in this round of centralized procurement will increase The opening of the bid is just around the corner The outflow of the minutes of the second round of centralized procurement meeting is not the same as the expansion after the first batch of pilot volume procurement The regions involved in the volume procurement include 31 provinces and autonomous regions in China, and the bidding procurement is still organized by Shanghai Pharmaceutical centralized bidding procurement management office Near the bid opening, the policy interpretation of the second round of centralized purchase and the supplementary documents of Shanghai region has recently flowed out in the industry, mainly involving the rules of winning and the fate and trend of non winning drugs According to the document, the second round of centralized purchase is not based on specifications, but on the whole variety In short, there is only one medium-sized enterprise in a region for each variety, and all specifications of this variety in the region are exclusively supplied by one medium-sized enterprise This has not been mentioned in the previous volume purchase In addition, the purchase volume and purchase cycle have also been adjusted If there is one selected enterprise in this centralized purchase, the purchase quantity is 50%, and the purchase cycle is one year; if there are two selected enterprises, the purchase quantity is 60%, and the purchase cycle is two years; if there are three selected enterprises, the purchase quantity is 70%, and the purchase cycle is two years; if there are four or more selected enterprises, the purchase quantity is 80%, and the purchase cycle is three years If it is completed in excess in advance, the selected enterprise can continue to supply according to the selected price until the end of the purchase cycle For the use of unselected drugs, the supplementary documents of Shanghai region require that the unselected drugs can be purchased and used on the premise of ensuring the dosage of the unselected drugs, but the quantity shall not exceed the selected varieties after being converted according to the proportion relationship The price of drugs not selected will go through gradient price reduction, and those who are not willing to accept the price reduction will lose the purchasing qualification Specifically, in this bidding, if one of the procurement varieties includes the original research and development pharmaceutical enterprises, there are more than three generic pharmaceutical enterprises (> 1 + 3), and all designated medical institutions and pharmacies will no longer purchase other varieties that have not been evaluated; for the time being, the price of the varieties that have not been evaluated does not reach 1 + 3, and the price of the varieties that have not been evaluated will be further adjusted below the selected price If the enterprise is not willing to reduce the price, it may lose the qualification to supply in Shanghai After the introduction of the second round of belt quantity purchase rules, the supplementary documents in Shanghai followed closely Based on the current trend, it can be seen that it is still very important for enterprises to compete in the top three With the deepening of 4 + 7 belt quantity purchase and the assistance of consistency evaluation, the pharmaceutical industry will face another round of brand shuffling test Note: the data in this paper refer to the Internet, some of which are based on the public information The above is for reference only If there is any omission, please correct it.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.